This episode reviews two recent papers on the practice-changing BEe-HIVe study, which assessed efficacy of a relatively new hepatitis B vaccine (known as HepB-CpG, or trade name Heplisav-B) for persons with HIV, and the resulting clinical implications. View episode transcript and references at www.hiv.uw.edu. This podcast explores practice-changing issues and updates in HIV diagnosis, management, and prevention. The three podcast hosts include Lead Editor Dr. Brian Wood, Professor of Medicin...
All content for National HIV Curriculum Podcast is the property of National HIV Curriculum and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This episode reviews two recent papers on the practice-changing BEe-HIVe study, which assessed efficacy of a relatively new hepatitis B vaccine (known as HepB-CpG, or trade name Heplisav-B) for persons with HIV, and the resulting clinical implications. View episode transcript and references at www.hiv.uw.edu. This podcast explores practice-changing issues and updates in HIV diagnosis, management, and prevention. The three podcast hosts include Lead Editor Dr. Brian Wood, Professor of Medicin...
The ANCHOR Study: Does Treatment of Anal HSIL Prevent Anal Cancer?
National HIV Curriculum Podcast
16 minutes
9 months ago
The ANCHOR Study: Does Treatment of Anal HSIL Prevent Anal Cancer?
This episode reviews a landmark study published in 2022 that aimed to answer the question of whether treating anal high-grade squamous intraepithelial lesions (HSIL) prevents anal cancer for persons with HIV, a question that was previously unanswered and that was key to informing the new anal cancer screening guidelines. View episode transcript and link to the article at www.hiv.uw.edu. This podcast explores practice-changing issues and updates in HIV diagnosis, management, and prevention. T...
National HIV Curriculum Podcast
This episode reviews two recent papers on the practice-changing BEe-HIVe study, which assessed efficacy of a relatively new hepatitis B vaccine (known as HepB-CpG, or trade name Heplisav-B) for persons with HIV, and the resulting clinical implications. View episode transcript and references at www.hiv.uw.edu. This podcast explores practice-changing issues and updates in HIV diagnosis, management, and prevention. The three podcast hosts include Lead Editor Dr. Brian Wood, Professor of Medicin...
